KRIBIOLISA™ Eluvixtamab ELISA

SKU: KBI1757 Category:

₹85,000.00

Enzyme Immunoassay for the estimation of Eluvixtamab in serum and plasma.

About the kit:
– Uses two anti-idiotypic monoclonal antibodies in direct sandwich format which ensures higher specificity, and low cross reactivity.
– Recovery rates are between 85 – 115%
– Validated as per US FDA guidelines for Bioassays
– Precision CV<10%


Availability: 3 – 4 weeks | Pack Size: 1 x 96 wells

Add to wishlist

Description

Background:
Eluvixtamab is a bi-specific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) CD33 fused to one that is directed against the CD3 antigen found on T lymphocytes. It was designed as a treatment for acute myeloid leukemia, but is not currently under any trials.

Intended Use:
For Estimation of Eluvixtamab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. please connect with us for optimisation.









If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!

View more details about our Publication Reward

Additional information

Species

Human
Biomarker Estimation

measures free drug
Sample Type

Serum (100 ul), EDTA Plasma (100 ul), Heparin Plasma (100 ul), Citrate Plasma (100 ul)
Calibration Range

0 ng/ml – 2000 ng/ml
Detection Method

Colorimetric @ 450nm
Specificity

80% – 120% to Eluvixtamab
Cross Reactivity

< 0.5% cross-reactivity observed with related biomarker.
Interference

No significant interference observed with available related molecules.
Regulatory Status

Research Use Only
Research Area

Biosimilars / Therapeutic Drug Monitoring / Bispecific Antibodies
Entez Gene ID

AMG-330 Human
Alternate Names / Synonyms

A cd33/cd3 bispecific t-cell engager antibody for acute myeloid leukemia therapy
Drug Bank Accession Number

DB17252
ELISA Type

Direct Sandwich Assay
Storage Temperature

Store the unopened product at 2-8?C. Do not use past expiration date.
Validation

The kit uses a biosimilar research grade standard / calibrator. The standard / calibrator has been validated against WHO/NIBSC standard and/or against commercially sourced innovator drug where available. Please refer the IFU for more details.
Disclaimer

Trade name indicated is for reference purposes only. It does not reflect any licences or patent usage. The tradename is the registered trademark of the respective owners only.
Long Name

Protein Based Therapies – Monoclonal Antibody

Related products